| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SLC41A1-L1 |
| WB Predicted band size | 62 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human SLC41A2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC41A2抗体的示例参考文献(仅供参考，建议通过学术数据库核实具体文献)：
---
1. **标题**: "SLC41A2 mediates magnesium transport in renal epithelial cells and its role in hypertension"
**作者**: A. Goytain et al.
**摘要**: 本研究利用针对SLC41A2的特异性抗体，通过免疫印迹和免疫荧光技术，证实了SLC41A2在肾脏上皮细胞中的定位及其镁离子转运功能。实验表明，SLC41A2表达下调与高血压模型中细胞内镁失衡相关。
2. **标题**: "Expression profiling of SLC41A2 in colorectal cancer using a novel monoclonal antibody"
**作者**: M. Tanaka et al.
**摘要**: 作者开发了一种高特异性抗SLC41A2的单克隆抗体，并应用于结直肠癌组织微阵列分析。结果显示，SLC41A2在肿瘤组织中表达显著升高，提示其可能作为癌症进展的生物标志物。
3. **标题**: "SLC41A2 regulates cellular magnesium homeostasis and neuronal excitability"
**作者**: S. Kolisek et al.
**摘要**: 通过Western blot和免疫组化技术，研究揭示了SLC41A2在中枢神经系统的分布及其对神经元镁稳态的调控作用。抗体特异性验证表明，SLC41A2缺失会导致神经元兴奋性异常。
4. **标题**: "Antibody-based detection of SLC41A2 in placental tissue: Implications for preeclampsia"
**作者**: L. Zhang et al.
**摘要**: 研究利用抗SLC41A2抗体检测胎盘组织，发现先兆子痫患者中SLC41A2表达异常降低，可能通过影响镁转运参与病理过程。实验验证了抗体的特异性及潜在临床应用价值。
---
**注意**：以上文献为示例性内容，实际研究需通过PubMed、Web of Science或Google Scholar等平台检索关键词(如"SLC41A2 antibody" + "application" / "validation")获取准确信息。
SLC41A2 (Solute Carrier Family 41 Member 2) is a magnesium transporter protein encoded by the *SLC41A2* gene, belonging to the SLC41 family involved in cellular magnesium homeostasis. It facilitates Mg²⁺ efflux across plasma membranes, playing a role in regulating intracellular Mg²⁺ levels critical for enzymatic functions, ion channel regulation, and nucleic acid stability. SLC41A2 is ubiquitously expressed, with higher levels in tissues like the kidneys, intestines, and placenta, suggesting its importance in systemic magnesium balance.
Antibodies targeting SLC41A2 are essential tools for studying its expression, localization, and physiological/pathological roles. These antibodies are typically developed in hosts like rabbits or mice using immunogenic peptides or recombinant protein fragments. They enable detection via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validation often includes knockout cell lines or tissues to confirm specificity.
Research utilizing SLC41A2 antibodies has explored its association with diseases, including cardiovascular disorders (linked to magnesium deficiency) and neurodegenerative conditions. Recent studies also investigate its potential role in cancer progression, as altered magnesium transport may influence cell proliferation and metastasis. Commercial SLC41A2 antibodies are available from suppliers like Sigma-Aldrich and Abcam, often accompanied by validation data. However, variability in antibody performance underscores the need for careful optimization in experimental settings.
×
